98 related articles for article (PubMed ID: 26676391)
1. Early Efficacy of an α1 Adrenoceptor Antagonist, Naftopidil, against Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.
Ishizuka O; Nishizawa O; Takeda M; Nomura T; Kagawa S
Low Urin Tract Symptoms; 2011 Sep; 3(2):79-85. PubMed ID: 26676391
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
3. Symptoms Predictive for Efficacy of Naftopidil in Patients with Benign Prostate Hyperplasia.
Funahashi Y; Hattori R; Yoshino Y; Matsukawa Y; Sassa N; Gotoh M
Low Urin Tract Symptoms; 2011 Sep; 3(2):113-7. PubMed ID: 26676397
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy of α1-Adrenargic Receptor Antagonist Naftopidil 75 mg/day in Patients with Benign Prostatic Hyperplasia.
Kadekawa K; Sugaya K; Ashitomi K; Nishijima S
Low Urin Tract Symptoms; 2010 Sep; 2(2):106-12. PubMed ID: 26676292
[TBL] [Abstract][Full Text] [Related]
5. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Yamaguchi S; Osanai H; Numata A; Watanabe M; Kakizaki H
Int J Urol; 2013 May; 20(5):513-9. PubMed ID: 23078534
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Masumori N; Hashimoto J; Itoh N; Tsukamoto T;
Scand J Urol Nephrol; 2007; 41(5):422-9. PubMed ID: 17853040
[TBL] [Abstract][Full Text] [Related]
7. Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
Tanuma Y; Tanaka Y; Takeyama K; Okamoto T
Urol Ann; 2016; 8(1):20-5. PubMed ID: 26834396
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia.
Shigemura K; Yamamichi F; Matsumoto M; Tanaka K; Yamashita M; Arakawa S; Fujisawa M
Low Urin Tract Symptoms; 2012 Sep; 4(3):136-9. PubMed ID: 26676620
[TBL] [Abstract][Full Text] [Related]
10. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
[TBL] [Abstract][Full Text] [Related]
11. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
[TBL] [Abstract][Full Text] [Related]
12. Nocturia Potentially Influences Maintenance of Sexual Function in Elderly Men with Benign Prostatic Hyperplasia.
Ishizuka O; Matsuyama H; Sakai H; Matsubara A; Nagaoka A; Takahashi S; Takeda M; Ozono S; Shiroki R; Shuin T; Hara I; Kakizaki H; Tsukamoto T; Yamanishi T; Yokoyama O; Kakehi Y; Nishizawa O;
Low Urin Tract Symptoms; 2013 May; 5(2):75-81. PubMed ID: 26663374
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia.
Griwan MS; Karthikeyan YR; Kumar M; Singh BJ; Singh SK
Urol Ann; 2014 Jul; 6(3):181-6. PubMed ID: 25125888
[TBL] [Abstract][Full Text] [Related]
14. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Kadekawa K; Sugaya K; Mukoyama H; Sakumoto M; Shimabukuro H; Shimabukuro S; Matayoshi Y; Onaga T; Ashitomi K; Nishijima S
Low Urin Tract Symptoms; 2016 May; 8(2):100-5. PubMed ID: 27111621
[TBL] [Abstract][Full Text] [Related]
15. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
16. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
18. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
19. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
20. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
